Couverture des analystes : ORGANIZATION ANALYST CONTACT Keay Nakae knakae@chardancm.com Sébastien Malafosse smalafosse@oddo.fr Arnaud Guérin guerin@portzamparc.fr Arsene Guekam aguekam@keplercheuvreux.com Membres du conseil d’administration: 36,75% du capital et 48,39% des droits de vote – au 31 décembre 2016 Membres du pacte d’actionnaires: 48,16% du capital et 63,42% des droits de vote – au 31 décembre 2016 Autres…
The masitinib mechanism of action has been demonstrated in ALS and is based on the targeting of mast cells and aberrant glial cells. AB Science completed a phase 2/3 study in ALS with positive results in a patient population accounting for 85% of the total population. Read More …
AB Science is a clinical-stage pharmaceutical company developing innovative drugs targeting diseases with unmet medical needs. Our two main compounds are developed in the field of oncology, inflammatory diseases and neurological degenerative disorders. Masitinib, AB Science main product, is well advanced clinically with positive phase 3 data in Amyotrophic Lateral Sclerosis (ALS), indolent severe systemic…
WHAT ARE THE INNOVATIONS FROM AB SCIENCE RESEARCH? Research by AB Science regarding masitinib, its flagship molecule, is aimed at providing innovative therapeutic solutions in three main areas of medicine: oncology, inflammatory diseases, and neurological disorders. AB Science hypothesized that mast cells play a key role in tumorigenesis (for example, pancreatic, prostate, colorectal); chronic…
30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.
19/04/2018 – AB Science will provide additional data through a reexamination procedure
Praesent nec lectus eu neque fringilla volutpat. Nulla tristique ullamcorper quam, ut dapibus massa hendrerit ac. Etiam a tempus lectus. Proin nibh nisi, vehicula non enim sed, venenatis faucibus orci. Fusce ut elementum nunc, vel eleifend sem.
Suspendisse ex justo, lacinia nec iverra bel, lacinia id lorem. Sed turpis eget sem accumsan viverra
Nulla dui fusce feugiat malesuada odiorbi nunc odio gravida at cursus nec luctus a lorem aecenas tristique orci acsemuis ultricies pharetra magna.
13/03/2018 – Current status and perspective for 2018.